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Abstract Genomic instability at microsatellite loci is a
hallmark of many cancers, including breast cancer. How-
ever, much of the genomic variation and many of the
hereditary components responsible for breast cancer
remain undetected. We hypothesized that variation at
microsatellites could provide additional genomic markers
for breast cancer risk assessment. A total of 1,345 germline
and tumor DNA samples from individuals diagnosed with
breast cancer, exome sequenced as part of The Cancer
Genome Atlas, were analyzed for microsatellite variation.
The comparison group for our analysis, representing heal-
thy individuals, consisted of 249 females which were ex-
ome sequenced as part of the 1,000 Genomes Project. We
applied our microsatellite-based genotyping pipeline to
identify 55 microsatellite loci that can distinguish between
the germline of individuals diagnosed with breast cancer
and healthy individuals with a sensitivity of 88.4 % and a
specificity of 77.1 %. Further, we identified additional
microsatellite loci that are potentially useful for distin-
guishing between breast cancer subtypes, revealing a pos-
sible fifth subtype. These findings are of clinical interest as
possible risk diagnostics and reveal genes that may be of
potential therapeutic value, including genes previously not
associated with breast cancer.
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Introduction
The American Cancer Society predicts 232,340 new cases
of invasive breast carcinoma (BC) will be diagnosed in
2013 and females have 1 in 8 chance of developing this
cancer within their lifetime. An individual’s predisposi-
tion, prognosis, and response to therapy of complex dis-
eases such as cancer are mediated to varying degrees by
their genomic makeup. Breast cancers have significant
known inherited or spontaneous components. However,
the accumulated knowledge from extensive studies, many
of which have focused on single nucleotide polymor-
phisms (SNPs), explains less than half of heritable
components to date. For example, several dozen variants
in the well-studied BRCA1 and BRCA2 genes account
for only 5 and 10 % of inherited BC susceptibility,
respectively [1–6], and the recent iCOS studies empha-
size that there is still a discrepancy between the known
BC susceptibility loci and the expected heritable com-
ponent of BC [7–9]. There is sustained debate between
those who believe the missing disease contributions will
be explained by rare variants with a large effect or
common variants with small effects. However, the truth is
probably somewhere in between as it is difficult to
explain by large SNP-based Genome Wide Association
Studies alone. We hypothesize that much of these sig-
nificant missing genetic components may be explained by
variation in parts of the genome, which have not been
explored previously, namely, microsatellite or repetitive
DNA loci, notably referred to as ‘‘Junk DNA’’ or more
recently ‘‘Dark Matter’’ [10]. Cancer is highly responsive
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to treatment when diagnosed early; therefore, there is a
significant advantage to identifying additional informa-
tive, actionable markers that may account for some of the
differences between the estimated heritability and the
portion of risk that can be explained by known genetic
polymorphisms.
Microsatellites are repetitive DNA regions that occur
throughout the genome, and variations within microsatel-
lites can affect cellular function through mechanisms
including promoting alternative splicing [11], altering
protein sequence [12], and affecting gene regulation [13,
14]. Several previous studies on microsatellite variation
and its implied instability in cancer focus on variation
found between the tumor and somatic genomes of an
individual at five mononucleotide ‘‘Bethesda’’ markers
[15], which capture a small fraction of variation from the
*1 million microsatellite loci [16]. While variation within
the larger set of loci has been generally understudied, two
recent technological advances have enabled us to thor-
oughly characterize microsatellite variation genome-wide:
(1) The public release of single-strand, high-throughput
next-generation sequence data [17–19]; and (2) The
development of algorithms and analytic approaches that
enable accurate genotype determination at numerous
microsatellite loci [20, 21].
Materials and methods
The genotypes of microsatellite loci found within 249
ethnically matched healthy female germlines, 656 BC
germline exomes, 689 BC tumors (656 matched to the
germline samples), and 212 healthy male germlines from
exome sequences available through the 1000 Genomes
Project (disease-free females and males) or TCGA (BC
patients) were computed individually from re-assemblies
as described in our previous publications with microsatel-
lite calling accuracy being estimated to be between 94.4
and 96.5 % [20, 21]. We restricted our analysis to those
49,297 microsatellite loci that were genotyped with suffi-
cient coverage (159) in at least 10 exomes from both the
healthy and BC populations, and compared the genotype
distribution at each locus for the population. Benjamini–
Hochberg False Discovery Rate (FDR) test was applied to
the datasets to identify informative loci that distinguish
breast cancer from healthy genomes. The sensitivity and
specificity of the combined 55 loci to differentiate breast
cancer genomes from the healthy genomes were computed
using the receiver-operating characteristic (ROC). The
genotypes at these loci created a profile used as a risk
assessment tool for classifying independent sets of the
healthy or BC exomes. Detailed methods are available in
the supplemental information.
Results
Many studies attempt to link the presence or absence of
specific mutations to a disease state. This has been a suc-
cessful strategy for discovering disease-associated genes;
however, complex disease states are frequently due to
additive effects from multiple common variants, as seen, for
example, in the multiple SNPs associated with telomere
maintenance and BC risk [22]. To uncover this type of
interaction, we must employ a methodology that examines
the frequency at which alleles are seen across multiple loci in
an affected population. However, focusing solely on the
frequency at which an allele is represented may result in
missing a significant shift in the frequency at which an allele
is heterozygous. Therefore, we have performed our analysis
on the frequency of genotypes within the examined popu-
lations, using an algorithm for genotyping microsatellite loci
that we previously designed [20, 21]. We employed this
methodology to determine the genotype of all microsatellite
loci in exome sequences from the healthy females from the
1000 Genomes Project [18] and in 656 germline exomes
from BC patients sequenced as part of TCGA [19] (Suppl.
Fig. 1). Comparison of the healthy females from different
ethnic backgrounds revealed that variation at some micro-
satellite loci was correlated with ethnicity. Therefore, we
selected 249 individuals of which 87.5 % were of European
Ancestry to represent the healthy population (1kGP-EUF)
because the microsatellite profile of the BC germline sam-
ples was the closest to these exomes (Suppl. Fig. 2), and we
did not have information on the ancestry of the BC germline
samples at this time.
For each microsatellite locus, the most frequent geno-
type in the 1kGP-EUF population was identified as the
modal genotype and the frequency of alternative genotypes
present within both populations was calculated. On aver-
age, 29,809 ± 4,688 and 34,849 ± 4,371 microsatellite
loci were genotyped per 1kGP-EUF and BC germline
sample, with 283 ± 134 and 426 ± 124 nonmodal geno-
types, respectively (Suppl. Table 1). We identified 55 loci
that each individually showed a statistically significant
difference in genotype distribution between 1kGP-EUF and
BC germline (two-sided Fisher’s p with adjusted p value
B0.01 by Benjamini–Hochberg to reduce FDR). A com-
parison of females from the 1kGP randomly divided into
two subgroups did not identify any significant loci using
this FDR cut-off, showing that normal variations at loci in
two similar populations are not significant using our
methods. Figure 1 shows how the genotype distributions
for the healthy and cancer populations differ for a sample
of the 55 loci, including both those at which there were
more nonmodal genotypes present in the healthy popula-
tion and those at which there were more nonmodal geno-
types in the BC population. The genotypes for the BC and
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1kGP-EUF exomes can be visualized in Fig. 2, where any
genotype that matched the modal genotype identified in the
1kGP-EUF exomes is coded in gray and all nonmodal
genotypes are red. 25.1 ± 13.1 and 31.3 ± 9.4 % of the 55
loci were genotyped in the 1kGP-EUF and BC germline
exomes, respectively, which is not surprising given that we
use very stringent conditions for coverage and alignment,
and because Lander–Waterman distributions in random
fragment sequencing limits the number of callable loci in
each sample [23]. Notably, for the 1kGP-EUF population,
the modal genotype at 24 % of the 55 loci is heterozygous,
whereas the modal genotype for 36.4 % of the 55 loci in
the BC germline exomes is heterozygous. This confirms
that we are able to identify loci where the modal genotype
is different between the BC and healthy populations. This
is important because we are not identifying novel/rare
alleles but noting that individuals with BC are more fre-
quently heterozygotic at these loci. Analysis of the geno-
type distributions at the 55 loci revealed that 80 % (44/55)
of the loci are in Hardy–Weinberg equilibrium in the
1kGP-EUF samples, while only 40 % (22/55) are in
Hardy–Weinberg equilibrium for the BC germline (Suppl.
Table 2), raising the possibility that there is a reduction in
selective pressure in BC germline genomes that may result
in the increased susceptibility to BC.
Thirty-two of the genes associated with the 55 microsat-
ellite loci have previously been associated with cancer, and
18 are specifically linked to BC (Table 1). 49 of the same loci
are located in introns, of which 24 are within 50 nt of an
exon/intron boundary; three additional loci are intergenic.
Notably, four are in the 30UTRs of PIAS2, WWC3, MT1X,
and TBP, and one is exonic (a CAG repeat in FAM157A; see
Suppl. Fig. 3 for detailed analysis of this variant).
The genotypic differences at these 55 loci appear to
have two effects on the likelihood of BC. At 30 of the 55
loci, the presence of a nonmodal genotype is potentially
protective against BC (relative risk of \0.6; Suppl.
Table 2), whereas at 25 of the loci, a nonmodal genotype
appears to promote BC (relative risk[1.3). Gene ontology
enrichment analysis showed that genes involved in notch
Fig. 1 Individual microsatellite loci vary significantly between breast
cancer and healthy genomes. Genotype distributions for a represen-
tative subset of our 55 signature loci are shown. Gray bars represent
genotypes present in the healthy population, and red bars represent
genotypes in the BC samples
Table 1 Many of the genes associated with our 55 signature
microsatellite loci are known to be associated with cancer generally,
specifically with BC, or are involved in other cellular pathways
associated with cancer
Cancer NUFIP1, KDM1A, SPHK2, STC1, PIAS2, MLL,
TLN2, CUL1, POP4, PDGFRA, NCOR1, MME,
RASA1, ANAPC7, HSP90AA1, FANCI, WRN, TBP,
DNAH3, MT1X, PTPN22, NUP54, ADAM2, KIF1B,




NUFIP1, KDM1A, SPHK2, STC1, PIAS2, MLL,
TLN2, CUL1, POP4, PDGFRA, NCOR1, MME,
RASA1, ANAPC7, HSP90AA1, FANCI, WRN, TBP
Cell cycle CUL1, PTPN22, KIF1B, DNAH3, PDGFA, CCDC46,
WRN, MICALL1, ANAPC7
Apoptosis CUL1, SPHK2, ADAM2, PDGFRA, PDCD6IP
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signaling were enriched among those potential BC-pro-
moting loci, while the set that potentially protects against
BC includes proteins known to be involved in maintaining
genomic stability (e.g., WRN, FANCI, HSP90) and pro-
grammed cell death (e.g., PDCD6IP). Supplementary
Fig. 4 highlights some of the genes involved in signaling
pathways including p53, integrin, and MAPKK pathways.
We performed a similar analysis on the 508 BC germ-
line exomes that were classified as ‘‘white’’ once the
information on the ancestry of the BC samples was made
available. This analysis identified a set of 52 microsatellite
loci, of which 42 overlapped with the original 55 loci set.
Of the loci that ‘‘fell out’’, 9 loci fell below our statistical
cut-offs (had adjusted p-values of 0.05–0.01). In addition,
gene ontology analysis of the 52 loci was similar to that of
the original 55 loci. This analysis not only gives us confi-
dence in our original loci set as robust, but also shows that
there are likely additional informative loci that can be
identified as more BC exomes are available.
Risk classifier
We used the frequency of modal or nonmodal genotypes at
each of the original 55 informative loci within the BC
population relative to the 1kGP-EUF population to create a
breast cancer profile, i.e., we assigned a ‘‘modal’’ or
‘‘nonmodal’’ designation for each of the loci depending on
the overall consensus for the BC germline samples in
relation to the 1kGP-EUF. We then determined for each
individual sample whether it matched the BC cancer profile
at each locus at which it was genotyped. Figure 3 shows
the distribution of exomes based on the number of geno-
types at the 55 signature loci that match the cancer profile.
Using the false positive and false negative rates within the
training set, we were able determine the ROC for the 55
loci. By means of maximizing the area under the ROC
curve, we determined the optimal cut-off for a classifier as
having 76 % of the 55 BC loci matching the breast cancer
genotype profile (Suppl. Fig. 5). We were then able to
classify the BC germline exomes as ‘‘cancer-like’’
(C76 %) or the healthy (\76 %) with a sensitivity of
88.4 % and a specificity of 77.1 % (Fig. 3). A similar risk
classifier analysis done using the 52 loci from the ‘‘white’’
BC exomes had the same high sensitivity (88.4 %), but the
specificity was only 59 % (Suppl. Fig. 5B). Using these
risk classifiers on a set of BC tumor samples, we identified
88.1 % of the BC tumor exomes as cancer-like using the 55
loci set from all BC exomes and 88 % of the ‘‘white’’ BC
Fig. 2 Modal and nonmodal genotypes present in germline exomes
of BC and healthy individuals. Individuals with BC show a distinct
genotype pattern compared with the healthy females. Gray modal, red
nonmodal. luminal A [LA], luminal B [LB], ERBB2/HER2?
[HER2], and basal-like [BL], UNKNOWN = no indicated subtype,
BC germline IND [independent set of BC germline exomes of mixed
ethnicity], BC germline IND-2 [independent set of BC germline
exomes of ‘‘white’’ ethnicity], 1kGP-EUF, IND [independent set of
healthy females, aka 1kGP-EUF IND]
794 Breast Cancer Res Treat (2014) 145:791–798
123
tumor exomes as ‘‘cancer-like’’ using the 52 loci from the
‘‘white’’ BC exomes, a difference that was not statistically
significant from the number of germline BC samples that
were cancer-like in either case (Fig. 3; Suppl. Fig. 6). This
is in contrast to the 1kGP-EUF samples, of which 77.1 %
were normal, and only 22.9 % were cancer-like (Fig. 3;
Table 2). In addition, two independent sets of BC germline
samples (BC IND with 60 samples of mixed ethnicity and
BC IND-2 with 137 samples that were all ‘‘white’’) showed
a similar frequency of exomes classified as ‘‘cancer-like’’,
whereas the other healthy individuals, including males and
nonEuropean females, and an independent set of 52
European females are more similar to the 1kGP-EUF ex-
omes (Table 2; Suppl. Fig. 7).
The 55 signature loci were derived from the analysis of
BC germline exomes regardless of BC subtype. We divided
the BC samples into their subtypes and a set of samples
where a subtype was not specified (unknown) to determine
if we are able to classify exomes according to subset.
Surprisingly, the BC ‘‘unknown’’ exome samples appeared
to have a distinct profile within the 55 informative loci,
distinguishing them from established BC subtypes (Fig. 2).
Based on the ‘‘unknown’’ classification, we do not know if
these samples constitute individuals with BC which would
be consistent with a known subtype but were simply not
classified or if these samples are unidentifiable using tra-
ditional subtype classification methods. We suggest that the
latter explanation is more consistent with their distinct
genotype profile within our loci set. The two independent
sets of BC germline samples had similar genotype profiles
to those BC germlines for which there was a subtype
specified as opposed to the 1kGP-EUF samples or the
unknown BC germline samples (Fig. 2), whereas the
independent set of healthy European females (IND) was
more similar to the 1kGP-EUF. We re-analyzed all
microsatellites for each subtype with respect to the 1kGP-
EUF to identify additional loci that are associated with
each or multiple subtypes. We found additional informative
loci that distinguish the LA and ‘‘unknown’’ subtypes in
addition to the 55 that distinguish all BC from the healthy
genomes (Fig. 4). For the LA subtype, we identified four
informative loci, two of which were unique to the LA
subtype. For the ‘‘unknown’’ subtype, there were 41
informative loci identified, 22 of which were unique and
included loci in genes involved in cell–cycle control,
chromatin remodeling and programmed cell death. That
there are loci unique to specific BC subtypes indicates that
our method may be useful for distinguishing between BC
Fig. 3 BC exomes have a
higher average percentage of
loci matching the breast cancer
profile. Distributions of exomes
based on their genotypes at the
55 BC-associated microsatellite
loci. We classify genomes
having C76 % of callable
genotypes as cancer-like and
those having \76 % as similar
to the healthy population
Table 2 Classification of exome sets using our BC risk classifier
Sample set Number of exomes % Healthy % Cancer-like
1kGP-EUF 249 77.1 22.9
1kGP-EUF IND 52 61.5 38.5
BC germline 656 11.6 88.4
BC IND 60 15.0 85.0
BC IND-2 137 14.6 85.4
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subtypes. No loci passed our rigorous statistical require-
ments for the luminal B (LB), ERBB2/HER2? (HER2), or
basal-like/triple negative (BL) subtypes, likely because of
the smaller number of exomes available for these BC
subtypes.
Breast cancer tumor versus germline exomes
595 of the BC germline exome samples had matched
tumor/germline exome data available (Suppl. Table 1).
Supplementary Fig. 8 shows the genotypic concordance
between the BC germline and tumor samples. For the 496
matched samples where we could genotype at least 10 of
the 55 loci in the germline and tumor, 75.2 % were cases
where the tumor and germline were cancer-like, 8.9 % the
tumor was cancer-like, while the germline was not; and
12.1 % the germline was cancer-like, while the tumor was
not (Suppl. Table 1). There were only 3.8 % of cases
where neither the germline nor the matched tumor was
cancer-like. It is important to note that no exome was
sequenced with [159 coverage at all 55 loci (Fig. 2), and
so in instances where only one of the matched germline and
tumor exomes was classified as cancer-like, the difference
may be due to differences in which loci could be genotyped
for a given sample. Comparison of the tumor and matched
germline exomes with our analytic pipeline did not reveal
additional loci that were statistically different. This is not
unexpected given that microsatellite instability associated
with tumors could re-distribute genotypes nonuniformly
across a population or even within a single individual. This
analysis highlights the strength of our methodology for
identifying cancer-like exomes from germline sequencing
data.
Thirty-three germline exome sequenced samples had
known mutations in TP53 [19]; of these, 28 were identified
by our method as cancer-like. In addition, 15 samples were
identified as having a potential mutation in BRCA1 or
BRCA2 of which 14 are identified by our method as
cancer-like (Suppl. Fig. 9). That the majority of exomes
with BRCA/TP53 mutations are also classified by our
method as cancer-like is not surprising since these genes
are important for maintaining genomic stability. Our
measure is not restricted to identifying individuals carrying
these known high-risk markers allowing us to identify 541
individuals who did not carry these disease–predisposing
mutations as cancer-like.
RNAseq data were available for 636 of the BC tumors
and 87 of the BC germline samples that were in our BC
exome sets. We performed genotype prediction from the
RNAseq data for 18,148 exonic microsatellite loci that
were potentially callable in the matched RNAseq geno-
types and the respective genotypes in the germline and
tumor samples. At 99.98 % of loci, the predicted genotype
from RNAseq was consistent with the genotype determined
from the matched exome sequencing. Those loci that were
genotyped differently between the matched exome and
RNASeq data were located at 72 loci,1 none of which is in
genes associated with our 55 loci. However, genes asso-
ciated with loci that differ between BC germline and
RNAseq data are enriched for the VEGF signaling path-
way, which influences vascular growth and angiogenesis.
These loci may be additional biomarkers for alternatively
spliced transcripts that may contribute to BC.
Gene set enrichment analysis (GSEA) [24, 25] indicated
that the 55 informative loci and those loci that were
identified in the individual subtypes were enriched for
association with genes expression of which positively
correlates with BRCA1. We analyzed the RNAseq data to
identify additional potential shifts in gene expression that
might correlate with BC. We were able to analyze the
expression level for 52 of the genes in the BC tumor ex-
omes but only 46 genes in the BC germline samples
because gene expression data were provided for 304 tumor
samples but only 39 germline samples from the TCGA
[19]. No expression information was available for
FAM157A or TRG. Of the signature loci, 48 had previ-
ously been shown to have some levels of expression in
breast tissue (Suppl. Table 2; [26]). Comparing all germ-
line and tumor samples, analysis of the expression levels of
the genes associated with the 55 informative microsatellite
loci revealed that seven of these showed [29 increased
expression in tumors, while four showed decreased
expression (Suppl. Table 3). One gene in the germline set
(CRISP1) and one gene in the tumor set (ABHD12B)
showed [29 difference in expression between individuals
who had a genotype matching the BC profile, and those
who did not. In both cases, the individuals with a genotype
that matched the BC profile showed a higher expression
level.
Fig. 4 Overlap of informative loci distinguishing BC subtypes
1 Large data file, content available upon request.
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Microsatellite variation at intronic loci may result in
alternatively spliced transcripts [11] that have the potential
to contribute to oncogenesis, with estimates that *95 % of
multi-exon genes exhibit alternative splicing [27]. In
addition, 49.0 % of the intronic loci were within 50 nt of
an exon/intron junction, a higher frequency than expected
given that only 3.4 % of all intronic microsatellites that
were genotyped in at least one exome sample were within
this boundary. This led us to hypothesize that RNA splicing
is affected. We used Cufflinks [28] to identify possible
alternative splicing events in transcripts from genes con-
taining the signature loci. For those loci at which we had
data about both the transcript splicing and genotype data,
we found that, for the germline and tumor sets respectively,
84.9 and 81.5 % of the transcripts from loci genotype of
which matched the BC profile showed possible alternative
splicing compared with 77.4 and 79.8 % of those tran-
scripts from loci genotype of which did not match the
profile.
Ten of the genes associated with the 55 loci are targets
of, or affected by, pharmaceuticals several of which are
prescribed or in clinical trials for BC (Suppl. Table 4). This
is *1.29 greater than expected given the drug–target
interactions within the CancerResource database [29].
Thus, our analysis may provide novel drug–targets or drug
re-positioning opportunities for additional or combinatorial
BC treatment plans.
Discussion
In summary, the comparison of ‘‘healthy’’ and breast can-
cer patient exomes at microsatellite loci revealed variations
in nonmodal genotype frequency, while comparably, only a
small number of variations were seen between matched
breast cancer germline and tumor exomes. We applied our
microsatellite genotyping pipeline to nearly 50,000
microsatellite loci from BC and disease-free females and
identified 55 loci at which the frequency of nonmodal
genotypes was statistically significantly different between
the two populations, of which 30 showed a risk ratio below
0.6, while 25 had a risk ratio greater than 1.3. Importantly,
the presence or the absence of nonmodal genotypes at the
55 loci was used to create a ‘‘BC profile’’ that can be used
as a risk classifier. The overwhelming majority of exomes
classified as cancer-like did not carry any known BC-
associated mutation. If the analysis is confirmed in inde-
pendent matched cohorts, then an assay consisting of these
55 loci might be clinically informative with a sensitivity of
88.4 %, which exceeds current test performance, while the
specificity is about two fold which would be expected,
given that 12 % of the ‘‘healthy’’ female population will be
future BC patients. Many of the 55 loci are within genes
implicated in breast cancer, while several represent
potential new drug–targets with protein variants resulting
from alternative splicing or, in one case, an exonic
variation.
Such surveys of large cohorts of the microsatellite
genomes of the affected individuals and the matched
‘‘healthy’’ populations could be a platform for identifying
clinically actionable risk diagnostics, companion diagnos-
tics, and drug–targets when applied to complex multigenic
diseases for which disease severity, therapy response, and
other metadata are known.
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